{rfName}
Ou

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Salazar RAuthorSureda AAuthorPlaja AAuthorCucurull MAuthorMesía RAuthorBrunet JAuthorMaluquer CAuthorCarmona-García McAuthor

Share

Publications
>
Article

Outcomes of the SARS-CoV-2 omicron (B

Publicated to:Lancet Oncology. 23 (7): 865-875 - 2022-07-01 23(7), DOI: 10.1016/s1470-2045(22)00273-x

Authors: Pinato, DJ; Aguilar-Company, J; Ferrante, D; Hanbury, G; Bower, M; Salazar, R; Mirallas, O; Sureda, A; Plaja, A; Cucurull, M; Mesia, R; Townsend, S; Jackson, A; Dalla Pria, A; Newsom-Davis, T; Handford, J; Sita-Lumsden, A; Apthorp, E; Vincenzi, B; Bertuzzi, A; Brunet, J; Lambertini, M; Maluquer, C; Pedrazzoli, P; Biello, F; Sinclair, A; Bawany, S; Khalique, S; Rossi, S; Rogers, L; Murphy, C; Belessiotis, K; Carmona-García, MC; Sharkey, R; García-Illescas, D; Rizzo, G; Perachino, M; Saoudi-Gonzalez, N; Doonga, K; Fox, L; Roldán, E; Gaidano, G; Ruiz-Camps, I; Bruna, R; Patriarca, A; Martinez-Vila, C; Cantini, L; Zambelli, A; Giusti, R; Mazzoni, F; Caliman, E; Santoro, A; Grosso, F; Parisi, A; Queirolo, P; Aujayeb, A; Rimassa, L; Prat, A; Tucci, M; Libertini, M; Grisanti, S; Mukherjee, U; Diamantis, N; Fusco, V; Generali, D; Provenzano, S; Gennari, A; Tabernero, J; Cortellini, A

Affiliations

ASST Cremona, Multidisciplinary Breast Pathol & Translat Res Un, Cremona, Italy - Author
ASST Papa Giovanni XXIII, Oncol Unit, Bergamo, Italy - Author
Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Ctr Documentaz Osteonecrosi, Alessandria, Italy - Author
Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Mesothelioma Unit, Alessandria, Italy - Author
Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Oncol Unit, Alessandria, Italy - Author
Barts Hlth NHS Trust, Med Oncol, London, England - Author
Careggi Univ Hosp, Med Oncol, Florence, Italy - Author
Catalan Inst Oncol, IGTP, B ARGO Grp, Med Oncol Dept, Badalona, Spain - Author
Chelsea & Westminster Hosp, Dept Oncol, London, England - Author
Chelsea & Westminster Hosp, Natl Ctr HIV Malignancy, London, England - Author
CIBERONC, Oncobel & Program IDIBELL, ICO Hosp, Dept Med Oncol, Barcelona, Spain - Author
Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain - Author
Fdn IRCCS Ist Nazl Tumori, Med Oncol 2, Milan, Italy - Author
Fdn IRCCS Policlin San Matteo, Med Oncol Unit, Pavia, Italy - Author
Fdn Poliambulanza Ist Osped, Med Oncol Unit, Brescia, Italy - Author
Fundacio Althaia Manresa, Manresa, Spain - Author
Guys & St Thomas NHS Fdn Trust, Med Oncol, London, England - Author
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain - Author
Humanitas Univ, Dept Biomed Sci, Milan, Italy - Author
IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors, Barcelona, Spain - Author
IEO Ist Europeo Oncol, Melanoma & Sarcoma Med Treatment Unit, Milan, Italy - Author
Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London SW7 2AZ, England - Author
Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain - Author
Inst Oncol VHIO, Barcelona, Spain - Author
IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Milan, Italy - Author
IRCCS Osped Policlin San Martino, Med Oncol Dept, Genoa, Italy - Author
Ist Tumori Giovanni Paolo II, IRCCS, Bari, Italy - Author
Kings Coll London, Med Sch, London, England - Author
Kings Coll London, Translat Oncol & Urol Res TOUR, Sch Canc & Pharmaceut Sci, London, England - Author
Maggiore della Carita Hosp, Novara, Italy - Author
Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy - Author
Medical Oncology Unit, Spedali Civili, Brescia, Italy - Author
Medical Oncology, Careggi University Hospital, Florence, Italy - Author
Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain - Author
Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain - Author
Northumbria Healthcare NHS Fdn Trust, Resp Dept, North Shields, England - Author
Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy - Author
Policlin Univ Campus Biomed, Rome, Italy - Author
Policlinico Universitario Campus Bio-Medico, Rome, Italy - Author
Polytech Univ Marche Reg, AOU Osped Riuniti, Med Oncol, Ancona, Italy - Author
Spedali Civil Brescia, Med Oncol Unit, Brescia, Italy - Author
St Andrea Hosp, Med Oncol, Rome, Italy - Author
Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy - Author
Univ Barcelona, IDIBELL, ICO Hosp, Haematol Dept, Barcelona, Spain - Author
Univ Bari Aldo Moro, Dept Interdisciplinary Med DIM, Sect Med Oncol, Bari, Italy - Author
Univ Coll London Hosp, Canc Div, London, England - Author
Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Genoa, Italy - Author
Univ Hosp Josep Trueta, Catalan Inst Oncol, Dept Med Oncol, Girona, Spain - Author
Univ Pavia, Dept Internal Med & Med Therapy, Pavia, Italy - Author
Univ Piemonte Orieritale, Dept Transiat Med, Unit Med Stat, Novara, Italy - Author
Univ Piemonte Orieritale, Div Haematol, Novara, Italy - Author
Univ Piemonte Orieritale, Div Oncol, Novara, Italy - Author
Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy - Author
UVic UCC, IOB Quiron, Inst Oncol VHIO, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Dept Hematol, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Infect Dis, Barcelona, Spain - Author
Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain - Author
Velindre Canc Ctr, Cardiff, Wales - Author
See more

Abstract

Keywords

efficacyimmunogenicityAd26 cov2 sAd26.cov2.s vaccineAdultAgeAgedAntineoplastic agentAntineoplastic protocolArticleBelgiumBnt 162b 2Cancer patientCancer regressionCancer stagingCase fatality rateClinical trialComparative studyComplicationConfidence intervalControlled studyCoronavirus disease 2019Covid-19Covid-19 testingDeathDisease outbreaksElasomeranEpidemicEuropeFemaleFollow upFranceGenderGermanyHealth care qualityHealth statusHematologic malignancyHormonal therapyHospitalizationHumanHumansMaleMedical historyMiddle agedMonoclonal antibodyMorbidityMrna 1273Multicenter studyNeoplasmNeoplasmsNonhumanOdds ratioOutcome assessmentOxygenOxygen therapyPandemicPatient registryPrevention and controlProtein tyrosine kinase inhibitorRegisterRegistriesRepeated drug doseRetrospective studiesRetrospective studySars-cov-2Sars-cov-2 alphaSars-cov-2 deltaSars-cov-2 omicronSars-cov-2 vaccineSingle drug doseSolid malignant neoplasmSpainTozinameranUnited kingdomVaccineeVaxzevria

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Lancet Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 4/241, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

This publication has been distinguished as a “Highly Cited Paper” by the agencies WoS (ESI, Clarivate) and ESI (Clarivate), meaning that it ranks within the top 1% of the most cited articles in its thematic field during the year of its publication. In terms of the observed impact of the contribution, this work is considered one of the most influential worldwide, as it is recognized as highly cited. (source consulted: ESI Nov 14, 2024)

And this is evidenced by the extremely high normalized impacts through some of the main indicators of this type, which, although dynamic over time and dependent on the set of average global citations at the time of calculation, already indicate that they are well above the average in different agencies:

  • Normalization of citations relative to the expected citation rate (ESI) by the Clarivate agency: 5.26 (source consulted: ESI Nov 14, 2024)
  • Field Citation Ratio (FCR) from Dimensions: 28.15 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-25, the following number of citations:

  • WoS: 55
  • Europe PMC: 45
  • OpenCitations: 55

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-25:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 78.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 78 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 54.75.
  • The number of mentions on the social network X (formerly Twitter): 69 (Altmetric).
  • The number of mentions in news outlets: 2 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Italy; United Kingdom.